GLP-1 agonists and muscle
3 papers in the library, strongest Moderate.
Graded Moderate · Scoping review of human studies on GLP-1 receptor agonists in older adults, though data on muscle mass and physical performance remain limited and inconsistent.
Papers 3
- Why GLP-1 Weight Loss Can Cost You Muscle After 60Moderate2026Current nutrition reportsGLP-1 drugs like Ozempic help older adults shed weight, but a lot of that loss can be muscle. This review warns about sarcopenia, the muscle wasting that makes aging riskier. The authors say pairing the drugs with strength training and enough protein may protect muscle.
- Why Muscle Quality Matters So Much on GLP-1 Weight Loss DrugsPreliminary2026Journal of Yeungnam medical scienceDrugs like Ozempic drop weight fast, but some of that loss is muscle, not just fat. This review argues that in older adults and people with diabetes, inactivity or poor nutrition, losing lean mass can push them toward frailty and fractures. The authors point to failing mitochondria (the tiny power plants in muscle cells) as a shared culprit behind both insulin resistance and muscle loss. Their proposed fix pairs the drugs with resistance training, enough protein and tracking of body composition.
- A New Drug Combo May Protect Muscle During Ozempic-Style Weight LossPreliminary2026Proceedings of the National Academy of Sciences of the United States of AmericaDrugs like semaglutide help people lose weight but often shrink muscle too. In obese mice, adding an experimental compound called a 15-PGDH inhibitor helped muscles repair and regrow after injury, without canceling out the weight loss. This points to a possible way to keep muscle while on GLP-1 drugs.
How this map is computed
A mark's size is the number of papers we hold on that pairing. It is a count, not a weighting by study design or sample size.
The fill shows the strongest grade in the cell. One Strong paper among four Preliminary ones still fills it dark, so open the cell to see the rest.
Grades and verdicts are assigned by a named person, never by counting.
An empty cell is a finding: nobody in our library has run that trial yet.